Eagle Health Investments LP Invests $15.76 Million in Boston Scientific Corporation $BSX

Posted by Brian Himes on Aug 20th, 2026

Boston Scientific logo Eagle Health Investments LP acquired a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 369,164 shares of the medical equipment provider’s stock, valued at approximately $15,756,000. Boston Scientific comprises approximately 2.6% of Eagle Health Investments LP’s investment portfolio, making the stock its 16th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in BSX. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the second quarter worth about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the fourth quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at approximately $26,000. Sfam LLC bought a new position in Boston Scientific in the 4th quarter worth approximately $29,000. Finally, Cresta Advisors Ltd. bought a new position in Boston Scientific in the 4th quarter worth approximately $33,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 3.1%

Shares of Boston Scientific stock opened at $52.02 on Thursday. The business has a fifty day simple moving average of $46.22 and a 200 day simple moving average of $58.22. The stock has a market cap of $75.39 billion, a PE ratio of 21.06, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its board has approved a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Activity

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig acquired 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last ninety days. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on BSX shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Barclays cut their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research note on Thursday, May 28th. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Robert W. Baird set a $56.00 price objective on Boston Scientific in a report on Thursday, July 30th. Finally, Raymond James Financial restated an “outperform” rating and set a $57.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $71.62.

View Our Latest Stock Report on BSX

About Boston Scientific

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.